HHS Seeks New Warning Labels for Testosterone Therapy
Testosterone replacement therapy could soon carry different warnings on its label after federal health officials said the science no longer supports long-standing cautions about heart and prostate risks.
The U.S. Department of Health and Human Services, through the Food and Drug Administration, announced it is requesting updates to prescribing information for testosterone products following a comprehensive review of new clinical data. According to HHS.gov, the changes would remove key limitations added in 2015 and revise prostate-related warnings that have shaped prescribing for a decade.
What HHS wants to change
The proposed updates target three areas of current labeling. First, FDA wants to remove the limitation of use stating that safety and effectiveness have not been established in men with age-related hypogonadism. That language was added in 2015 when evidence was limited and cardiovascular concerns were raised.
Second, the agency would update prostate cancer risk information. Current labels generally state TRT should not be used in men with known or suspected prostate cancer. Under the revision, therapy would be contraindicated only in men with metastatic prostate cancer.
Third, warnings about benign prostatic hyperplasia would be revised. The FDA review found clinical trial data do not demonstrate worsening symptoms in men with mild to moderate BPH, though evidence remains limited for severe cases.
“During Men’s Health Month, we are putting science back at the center of men’s healthcare,” HHS Secretary Robert F. Kennedy Jr. said in the announcement. “By updating testosterone therapy labels to reflect current evidence, we are giving patients and physicians clearer information, supporting informed medical decisions, and improving care for millions of American men.”
📰 Related: GLP-1 Drugs: The Promises and the Troubling Side Effects Nobody Told You About
Why the science shifted on heart and prostate risks
The change centers on the TRAVERSE trial, a large study involving more than 5,200 men with hypogonadism and increased cardiovascular risk. The trial found no meaningful increase in major adverse cardiovascular events, including heart attack and stroke, among men receiving testosterone therapy compared to placebo.
Based on those findings and other evidence, FDA concluded the 2015 limitation is no longer warranted. The agency is also adding TRAVERSE results to product labeling and removing previous cardiovascular warning language while retaining monitoring recommendations.
For prostate health, available clinical and epidemiologic data have not generally shown an increased risk of prostate cancer in men receiving TRT. According to Urology Times, the updates reflect reassessed cardiovascular data and limited long-term prostate evidence, though officials note uncertainties remain because prostate cancer can take years to develop.
FDA continues to recommend that providers assess risk, screen patients before treatment, and monitor during therapy.
📰 Related: Your Coffee Brewing Method Affects Cholesterol and Dementia Risk
What this means for access and prescribing
If finalized, the labeling changes could make it easier for physicians to prescribe testosterone for men with age-related low testosterone, not just those with classic hypogonadism from a known medical cause. HHS said the goal is clearer, evidence-based information rather than expanded marketing.
Health experts stress TRT is not a wellness shortcut and should be administered under physician guidance. The therapy treats symptoms but does not fix the underlying cause of low testosterone.
The move follows a similar action last year for women’s health, when HHS and FDA removed long-standing black box warnings on menopausal hormone therapy products. According to New York Post, not all physicians are convinced there is enough long-term data to support the broad rollback, highlighting ongoing debate in the field.
The agency did not provide a timeline for implementation, noting manufacturers will need to submit labeling supplements.
📰 Related: Can Sparkling Water Increase Your Risk of Colorectal Cancer?
How TRT works and who it's approved for
The FDA has approved testosterone replacement therapy for men with low testosterone levels due to hypogonadism, a condition where the testes do not produce enough testosterone. Causes include genetic disorders, injury, chemotherapy, or pituitary problems.
TRT is available as skin gels, injections, patches, pellets implanted under the skin, and oral pills. Treatment aims to improve symptoms such as low libido, fatigue, loss of muscle mass, and mood changes, though benefits vary by patient.
Officials emphasized that testosterone can be harmful if taken by men with normal levels or without proper monitoring, including risks of elevated red blood cell count and blood pressure changes identified in recent studies.
Key Takeaways
- HHS is requesting label updates to remove the 2015 limitation for age-related low testosterone
- Prostate cancer warning narrowed to only men with metastatic disease, not all suspected cases
- TRAVERSE trial of 5,200+ men found no meaningful increase in heart attack or stroke risk
- BPH warnings revised after data showed no worsening in mild to moderate cases
- No timeline given for when manufacturers must update labels
